Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

The Alzheimer's Drug Development Program is a funding opportunity that is set aside for medical research, specifically for pre-clinical and initial stage clinical trials (Phase I). The aim of this grant is to financially support the development of new drugs, both small-molecule and biologic. The fund is specifically interested in backing drug projects that focus on preventing Alzheimer's disease, slowing down its progression, or treating the cognitive and behavioral symptoms associated with the disease. Importantly, conducting a clinical trial is not a requirement to apply for this funding opportunity.